Bellevue Funds (Lux) - Bellevue AI Health Bellevue Funds (Lux) - Bellevue AI Health I2

Reference Data

ISIN LU2721086689
Valor Number
Bloomberg Global ID
Fund Name Bellevue Funds (Lux) - Bellevue AI Health Bellevue Funds (Lux) - Bellevue AI Health I2
Fund Provider Bellevue Asset Management AG Zürich, Switzerland
Phone: +41 44 267 67 00
E-Mail: info@bellevue.ch
Web: www.bellevue.ch
Fund Provider Bellevue Asset Management AG
Representative in Switzerland Waystone Fund Services (Switzerland) SA
Lausanne
Phone: 0041213111781
Distributor(s)
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The Sub-fund is an actively managed equity fund. The investment objective of the sub-fund is to achieve long-term capital growth by investing at least two thirds of the net assets of Bellevue AI Health in a portfolio of carefully chosen shares and preference shares of companies whose business activities have a strong focus on the provision and/or use of artificial intelligence (AI) in the health sector or whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries.
Peculiarities

Fund Prices

Current Price * 145.81 EUR 07.11.2024
Previous Price * 145.76 EUR 06.11.2024
52 Week High * 153.18 EUR 30.08.2024
52 Week Low * 132.42 EUR 24.01.2024
NAV * 145.81 EUR 07.11.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 10,358,378
Unit/Share Assets ***
Trading Information SIX

Performance

YTD Performance - -
YTD Performance (in CHF) - -
1 month -0.67% 07.10.2024
07.11.2024
3 months +2.30% 07.08.2024
07.11.2024
6 months +4.40% 07.05.2024
07.11.2024
1 year +10.11% 24.01.2024
07.11.2024
2 years - -
3 years - -
5 years - -

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 8.96%
UnitedHealth Group Inc 7.93%
Novo Nordisk AS Class B 4.95%
Johnson & Johnson 4.32%
AbbVie Inc 4.15%
Amgen Inc 4.04%
Merck & Co Inc 3.91%
Roche Holding AG 3.46%
AstraZeneca PLC 3.25%
Novartis AG Registered Shares 3.16%
Last data update 30.09.2024

Cost / Risk

TER *** 1.46%
TER date *** 30.06.2024
Performance Fee ***
PTR
Max. Management Fee *** 0.80%
Ongoing Charges ***
SRRI ***
SRRI date *** 31.10.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)